Natalizumab Antibodies and C-X-C Motif Chemokine Ligand 13 Serum Levels in Multiple Sclerosis Patients

Hadeel Abood Mohammed, Ahmed Abdul-Hassan Abbas, Nawfal Mahdi Shaheed

Abstract


Background: Natalizumab is a humanized monoclonal antibody that is an established therapy for relapsing–remitting multiple sclerosis (RRMS). A fraction of patients, however, form anti-drug antibodies that have the potential to lessen the efficacy of therapy. To counteract this, the current study aimed to determine the incidence of anti-natalizumab immunoglobulins and examine their relationship with serum levels of C-X-C motif chemokine ligand 13 (CXCL13). Since CXCL13 is a marker of immune activation, determination of levels may provide informative insights on therapeutic effect and interpatient variation.

Methods: The study was conducted between February and September 2021 and included sixty patients with multiple sclerosis who attended the Multiple Sclerosis Center in Baghdad Teaching Hospital and 30 healthy individuals as control group. The patients were on natalizumab for about one year and divided into two groups (30 responders and 30 non-responders); all of them were diagnosed by consultant physicians. Studied markers like CXCL13 and Natalizumab Abs were measured by ELISA.

Results: The presence of anti-natalizumab antibodies in non-responder patients, responder patients, and healthy controls was (5, 0, 0), respectively. There was a statistically significant relationship between the presence of anti-natalizumab and the CXCL13 protein serum level in patients with multiple sclerosis (MS) (p < 0.001).

Conclusion: The presence of anti-natalizumab antibodies and its significant correlation with serum levels of CXCL13 in MS patients could be an informative indicator towards natalizumab treatment.

Keywords: Multiple Sclerosis, C-X-C motif chemokine ligand 13, Natalizumab


Full Text:

PDF

References


McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs, (2013); 73(13): 1463-1481.

Hegen H, Auer M, Deisenhammer F. Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients. Drugs, (2016); 76(15): 1421-1445.

Sehr T, Proschmann U, Thomas K, Marggraf M, Straube E, et al. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. Journal of Neuroinflammation, (2016); 13(1): 164.

Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgün K. Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up. Frontiers in Neurology, (2018); 9(2018): 1071.

Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Multiple Sclerosis Journal, (2010); 17(3): 335-343.

Sorensen PS, Jensen PH, Haghikia A, Lundkvist M, Vedeler C, et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis Journal, (2011); 17(9): 1074-1078.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine, (2006); 354(9): 899-910.

Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Multiple Sclerosis Journal, (2013); 19(5): 593-600.

Deisenhammer F, Jank M, Lauren A, Sjödin A, Ryner M, et al. Prediction of natalizumab anti-drug antibodies persistency. Multiple Sclerosis Journal, (2019); 25(3): 392-398.

Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Multiple Sclerosis Journal, (2013); 19(9): 1204-1208.

DiSano KD, Gilli F, Pachner AR. Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis. Multiple Sclerosis Journal–Experimental, (2020); 6(4): 2055217320981396.

Festa ED, Hankiewicz K, Kim S, Skurnick J, Wolansky LJ, et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Multiple Sclerosis Journal, (2009); 15(11): 1271-1279.

Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology, (2009); 73(23): 2003-2010.

Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain, (2005); 129(1): 200-211.

Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annual Review of Immunology, (2005); 23(1): 127-159.

Okada T, Cyster JG. B-cell migration and interactions in the early phase of antibody responses. Current Opinion in Immunology, (2006); 18(3): 278-285.

Zotos D, Coquet JM, Zhang Y, Light A, D’Costa K, et al. IL-21 regulates germinal center B-cell differentiation and proliferation through a B-cell-intrinsic mechanism. Journal of Experimental Medicine, (2010); 207(2): 365-378.

Crotty S. The 1-1-1 fallacy. Immunological Reviews, (2012); 247(1): 133-142.

Victora GD, Nussenzweig MC. Germinal centers. Annual Review of Immunology, (2012); 30(1): 429-457.

Yu P, Wang Y, Chin RK, Martinez-Pomares L, Gordon S, et al. B-cells control the migration of a subset of dendritic cells into B-cell follicles via CXC chemokine ligand 13 in a lymphotoxin-dependent fashion. The Journal of Immunology, (2002); 168(10): 5117-5123.

Langenkamp A, Nagata K, Murphy K, Wu L, Lanzavecchia A, et al. Kinetics and expression patterns of chemokine receptors in human CD4+ T lymphocytes primed by myeloid or plasmacytoid dendritic cells. European Journal of Immunology, (2003); 33(2): 474-482.

Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, et al. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center–localized subset of CXCR5+ T cells. The Journal of Experimental Medicine, (2001); 193(12): 1373-1382.




DOI: http://dx.doi.org/10.62940/als.v12i3.2018

Refbacks

  • There are currently no refbacks.